Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Sep;271(9):5899-5910.
doi: 10.1007/s00415-024-12514-x. Epub 2024 Jul 9.

Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome

Darin T Okuda #  1   2 , Christina J Azevedo #  3 , Daniel Pelletier  3 , Tatum M Moog  4   5 , Saeed Moazami  3 , Sepideh Rezvani  3 , Francesca Bovis  6 , Maria Pia Sormani  6 , Aksel Siva  7 , Orhun Kantarci  8 , Christine Lebrun-Frénay  9 ; ARISE Study Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome

Darin T Okuda et al. J Neurol. 2024 Sep.

Abstract

Background and purpose: The first randomized placebo-controlled therapeutic trial in radiologically isolated syndrome (RIS), ARISE, demonstrated that treatment with dimethyl fumarate (DMF) delayed the onset of a first clinical event related to CNS demyelination and was associated with a significant reduction in new and/or newly enlarging T2-weighted hyperintense lesions. The purpose of this study was to explore the effect of DMF on volumetric measures, including whole brain, thalamic, and subcortical gray matter volumes, brainstem and upper cervical spine three-dimensional (3D) volumes, and brainstem and upper cervical spine surface characteristics.

Methods: Standardized 3T MRIs including 3D isotropic T1-weighted gradient echo images were acquired at baseline and end-of-study according to the ARISE study protocol. The acquired data were analyzed using Structural Image Evaluation Using Normalization of Atrophy (SIENA), FreeSurfer v7.3, and an in-house pipeline for 3D conformational metrics. Multivariate mixed models for repeated measures were used to analyze rates of change in whole brain, thalamic, subcortical gray matter, as well as change in the 3D surface curvature of the dorsal pons and dorsal medulla and 3D volume change at the medulla-upper cervical spinal cord.

Results: The study population consisted of 64 RIS subjects (DMF:30, placebo:34). No significant difference was seen in whole brain, thalamic, or subcortical gray matter volumes in treated vs. untreated RIS patients. A significant difference was observed in dorsal pons curvature with the DMF group having a lower least squares mean change of - 4.46 (standard estimate (SE): 3.77) when compared to placebo [6.94 (3.71)] (p = 0.036). In individuals that experienced a first clinical event, a greater reduction in medulla-upper cervical spinal cord volume (p = 0.044) and a decrease in surface curvature was observed at the dorsal medulla (p = 0.009) but not at the dorsal pons (p = 0.443).

Conclusions: The benefit of disease-modifying therapy in RIS may extend to CNS structures impacted by neurodegeneration that is below the resolution of conventional volumetric measures.

Keywords: 3D; Atrophy; Dimethyl fumarate; MRI; Radiologically isolated syndrome; Volumetrics.

PubMed Disclaimer

References

    1. Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, Ohayon J, Wu T, Cortese ICM, Reich DS (2019) Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol 76:1474–1483 - DOI - PubMed - PMC
    1. Azevedo CJ, Overton E, Khadka S, Buckley J, Liu S, Sampat M, Kantarci O, Lebrun Frenay C, Siva A, Okuda DT, Pelletier D (2015) Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm 2:e102 - DOI - PubMed - PMC
    1. Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, Mallott JM, Asteggiano C, Sacco S, Gundel TJ, Zhao C, Stern WA, Caverzasi E, Zhou Y, Gomez R, Ragan NR, Santaniello A, Zhu AH, Juwono J, Bevan CJ, Bove RM, Crabtree E, Gelfand JM, Goodin DS, Graves JS, Green AJ, Oksenberg JR, Waubant E, Wilson MR, Zamvil SS, Cree BAC, Hauser SL, Henry RG (2022) Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. Ann Neurol 91:268–281 - DOI - PubMed - PMC
    1. Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea RA, Rahmanzadeh R, Galbusera R, Lu PJ, Weigel M, Melie-Garcia L, Ruberte E, Siebenborn N, Battaglini M, Radue EW, Yaldizli O, Oechtering J, Sinnecker T, Lorscheider J, Fischer-Barnicol B, Muller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb JM, Remonda L, Wagner F, Vargas MI, Du Pasquier R, Lalive PH, Pravata E, Weber J, Cattin PC, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C (2022) Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol 79:682–692 - DOI - PubMed
    1. Calvi A, Clarke MA, Prados F, Chard D, Ciccarelli O, Alberich M, Pareto D, Rodriguez Barranco M, Sastre-Garriga J, Tur C, Rovira A, Barkhof F (2023) Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Mult Scler 29:352–362 - DOI - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources